# The Severity of Carotid Calcifications, but Not Fibroblast Growth Factor 23, Is Associated with Mortality in Hemodialysis: A Single Center Experience

**Authors:** Diana Moldovan

PMC · DOI: 10.3390/diseases13030073 · Diseases · 2025-02-28

## TL;DR

This study found that the severity of carotid calcifications, not FGF-23, is linked to higher mortality in hemodialysis patients over 8 years.

## Contribution

The study identifies carotid vascular calcifications as an independent predictor of mortality in hemodialysis patients.

## Key findings

- Carotid VC score over 4 predicts all-cause and cardiovascular mortality in HD patients.
- Diabetes, low albumin, and high CRP are also linked to higher mortality.
- FGF-23 was not associated with mortality outcomes in this cohort.

## Abstract

Background. The study goal was to assess the mortality effect of carotid vascular calcifications (VC), of fibroblast growth factor 23 (FGF-23), mineral markers, and comorbidities in hemodialysis (HD) patients. Methods. The influence of carotid VC severity, FGF-23, laboratory markers, clinical features, and comorbidities on mortality was analyzed in a cohort of 88 HD patients. The follow-up period lasted 8 years. The cut-off value for carotid VC was 4 for all-cause and cardiovascular mortality. Results. Carotid VC, diabetes, low serum albumin, high serum C-reactive protein (CRP), and the presence of cardiovascular diseases are associated with all-cause and cardiovascular mortality. Carotid VC score over 4 was an independent predictor of all-cause and cardiovascular mortality, along with diabetes, low albumin, and high CRP. FGF-23 was not found to be predictable for the study outcomes. Conclusions. The study documented in a cohort of patients prevalent in chronic HD that carotid VC predicts all-cause and cardiovascular mortality at 8 years and improves risk stratification, but FGF-23 is not associated with mortality. Other risk factors for all-cause and cardiovascular mortality were diabetes, inflammation, and malnutrition. However, future efforts are needed to assess whether a risk-based approach, including VC screening, improves survival.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** malnutrition (MESH:D044342), inflammation (MESH:D007249), diabetes (MESH:D003920), cardiovascular diseases (MESH:D002318), VC (MESH:D061205)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11941726/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11941726/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC11941726/full.md

---
Source: https://tomesphere.com/paper/PMC11941726